SOLV · Solventum Corp
Price
Snapshot
50 fields · last close| Market Cap | $15.74B |
| P/E | 10.26 |
| Float | 147.1M |
| Beta | 0.72 |
| Volatility | 18.0% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 80 |
| Price | 91.62 |
| Change | −0.89% |
| Prev Close | 92.44 |
| Open | 93.54 |
| Day Low | 91.34 |
| Day High | 94.12 |
| Avg Vol | 1 |
| Avg $ Vol | $84.81M |
| 52W High | 94.16 |
| 52W Low | 62.38 |
| 52W Pos | 92.0% |
| From High | −2.70% |
| From Low | +46.87% |
| Max DD 1Y | −27.46% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +3.19% |
| SMA 50 | +9.41% |
| SMA 200 | +18.51% |
| RSI (14) | 68.2 |
| Vol 30D | 33.5% |
| Vol 90D | 31.7% |
| 1Y Range | 62–94 |
| Daily bars | 506 |
| Perf Week | +1.66% |
| Perf Month | +5.68% |
| Perf Quarter | +12.16% |
| Perf Half Y | +30.60% |
| Perf Year | +29.47% |
| Perf YTD | +15.95% |
| Prev Day | −0.89% |
| Clavix | B+ |
| Debt / Eq | 1.00 |
| Curr Ratio | 1.23 |
| Int Cover | 7.7× |
| FCF Margin | 2.3% |
| Rev Growth | +2.2% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 12 / 47 |
What SOLV does
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally.
It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V.
site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers.
The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs.
The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms.
The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce.
Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
Clavix risk grade
regraded every trading daySOLV grades B+, 80 of 100. Steadiest on Macro Resilience (70), most exposed on Price Stability (62, mixed). 3 of the 4 weighted dimensions sit above the Health Care median. Ranks 12 of 47 in Health Care by Clavix score.
How rough the ride is
| SOLV | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.72 | 0.81 |
| Volatilityannualized | 18.0% | 20.4% |
| Max drawdown, past yearworst peak-to-trough fall | −27.5% | — |
| Typical daily movemedian absolute daily change | 1.11% | — |
| Days beyond ±3%of the last 252 sessions | 208% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| SOLV | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.72 | 0.81 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate55% of 47 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| SOLV | |
|---|---|
| 1 week | +1.7% |
| 1 month | +5.7% |
| Year to date | +15.9% |
| 1 year | +29.5% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| SOLV | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 22 Jun |
| Average score0 most bearish, 100 most bullish | 63 |
| Bullish · bearisharticles above 60 · below 40 | 20 · 4 |
| Directionarticles whose tone is improving vs worsening | 20 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 47 Health Care names Clavix covers; the tick is the sector median.
Growth
| SOLV | |
|---|---|
| Revenue growthyear over year | +2.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Health Care
47 companies| Metric | SOLV | Sector spread | Median |
|---|---|---|---|
| Beta | 0.72 | 0.81 | |
| Volatility | 18.0% | 20.4% | |
| P/E | 10.26 | 26.14 | |
| Debt / equity | 1.00 | 0.71 | |
| Current ratio | 1.23 | 1.58 | |
| FCF margin | 2.3% | 8.6% | |
| Interest coverage | 7.7× | 6.3× |
Recent news
most recent scored articles · the chip is the article’s score · click to openAn analyst-style piece notes that Solventum's growth is improving and the company has a higher earnings outlook and is cutting costs, but flags heavy debt and expected 2027 margin pressure as reasons for caution.
Wall Street Zen downgraded Solventum (SOLV) from a 'buy' rating to a 'hold' rating in a report issued on Saturday.
Solventum (SOLV) announced plans to spin off its $1.4 billion Health Information Systems (HIS) business to sharpen its MedTech focus and give the HIS unit more flexibility to pursue growth as an independent entity.
Solventum's (SOLV) analyst fair value estimate was revised upward from US$82.15 to US$93.15, a roughly 13% increase, following Q2 results, the planned Health Information Systems (HIS) separation, and reassessment of the company's MedTech focus.
Solventum (SOLV) beat Q2 CY2026 expectations with revenue of $2.21B (up 2.2% YoY) and adjusted EPS of $2.55 (33.8% above consensus), and raised full-year adjusted EPS guidance to $7.15 at the midpoint, though operating margin declined to 8.2% from 9.9% as the company navigates its 3M separation, ERP transition, and Health Information Systems business shift.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| COO | Cooper Companies Inc | A- | $13.78B | 57.71 | 0.81 | Compare |
| ZBH | Zimmer Biomet Holdings, Inc | B+ | $18.37B | 23.50 | 0.50 | Compare |
| BAX | Baxter International Inc | B | $13.22B | — | 0.67 | Compare |
| PEN | Penumbra Inc | A+ | $12.65B | 78.99 | 0.71 | Compare |
| BTSG | Brightspring Health Services Inc | B- | $12.15B | 32.56 | 1.86 | Compare |
| THC | Tenet Healthcare Corp | B- | $21.22B | 9.47 | 1.22 | Compare |
| DVA | DaVita Inc | B | $11.59B | 13.70 | 0.89 | Compare |
| GH | Guardant Health Inc | C+ | $21.61B | — | 1.73 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.